{"organizations": ["VBI"], "uuid": "55d5418c6214d68ee1f1fbae78068c4eab33854a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530635?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "PIPE grosses a total of $6.29mm for VBI Vaccines", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "PIPE grosses a total of $6.29mm for VBI Vaccines", "spam_score": 0.0, "site_type": "news", "published": "2015-08-19T02:40:00.000+03:00", "replies_count": 0, "uuid": "55d5418c6214d68ee1f1fbae78068c4eab33854a"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530635?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "PIPE grosses a total of $6.29mm for VBI Vaccines", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "PIPE grosses a total of $6.29mm for VBI Vaccines Deal Date: Aug-01-2015 / Deal # 201530635 Executive Summary \nVBI Vaccines Inc. (infectious disease vaccines) grossed $6.3mm through two private placements. It first sold 2.29mm common shares at $2.10 each (a 15% discount) and a day later it sold 715k shares at $2.08 (a 16% discount). The financing was led by new backer, RTW Investments, which was joined by returning shareholders Arch Ventures Partners and Perceptive Advisors, as well as 16 other investors, the majority of which were individuals. Some of the proceeds will fund ongoing vaccine development.", "external_links": [], "published": "2015-08-19T02:40:00.000+03:00", "crawled": "2015-08-19T18:04:05.474+03:00", "highlightTitle": ""}